



Salzburg
Cancer
Research
Institute

4th SALZBURG BREAST CANCER TALK 21. – 22.10.2022

MASTERING TRANSLATIONAL IMMUNO-ONCOLOGY

FRIDAY, 21st OCTOBER

12:30 – 13:30	Welcome & Business Lunch	
13:30–13:35	Introduction	Richard Greil (<i>Salzburg</i>)
13:35 – 15:05	Clinical and Translational Research <i>Chair: Richard Greil, Denise M. Wolf</i>	
13:35	Current evidence of immunotherapy in early breast cancer	Rebecca Dent (<i>Singapore, online</i>)
14:05	Predictive biomarkers for immunotherapy – findings from the I-SPY 2 trial	Denise M. Wolf (<i>California</i>)
14:35	Predictive factors for immune-related side effects	Amrita Basu (<i>California</i>)
15:05 – 15:30	Panel Discussion <i>Moderator: Richard Greil (Salzburg)</i>	all speakers
15:30 – 16:00	Coffee Break	
16:00 – 17:30	Innate and Adaptive Immune System <i>Chair: Fritz Aberger, Gabriel Rinnerthaler</i>	
16:00	Single-Cell spatial immune cell composition – findings from the NeoTRIPaPDL1 trial	Luca Gianni (<i>Milano, online</i>)
16:30	PD-L1 vs. TILs: analytic and diagnostic issues	Roberto Salgado (<i>Antwerp</i>)
17:00	Harnessing metabolic pathways to enhance antitumor immunity and immunotherapy	Pedro Romero (<i>Lausanne</i>)
17:30 – 18:00	Panel Discussion <i>Moderator: Richard Greil (Salzburg)</i>	all speakers
19:00	Dinner	

SATURDAY, 22nd October

08:30 – 10:40	Metabolism & Immunogenicity <i>Chair: Pedro Romero, Alexander Egle</i>	
08:30	Hypoxia-inducible metabolites shape T cell fate	Iosifina Foskolou (<i>Cambridge</i>)
09:00	Immune escape in breast cancer and its therapeutic relevance	Barbara Seliger (<i>Halle, online</i>)
09:30	Biobreak	
09:40	Influence on immunogenicity by the microbioma	Laurence Zitvogel (<i>Paris, online</i>)
10:10	Influence on immunogenicity by sex hormones	Berna C. Özdemir (<i>Bern, online</i>)
10:40 – 11:00	Panel Discussion <i>Moderator: Richard Greil (Salzburg)</i>	all speakers
11:00 – 11:30	Coffee Break	
11:30 – 12:30	New Treatment Strategies <i>Chair: Simon Gampenrieder, Niels Schaft</i>	
11:30	Immunotherapy strategies beyond PD1/PD-L1 inhibition	Giuseppe Curigliano (<i>Milano, online</i>)
12:00	CAR T-Cells in breast cancer	Niels Schaft (<i>Erlangen</i>)
12:30 – 12:55	Panel Discussion <i>Moderator: Richard Greil (Salzburg)</i>	all speakers
12:55	Closing Remarks	Richard Greil (<i>Salzburg</i>)
13:00 – 14:00	Business Lunch & Farewell	

Hotel Gersbergalm
Gersberg 37
5020 Salzburg

www.gersbergalm.at



Prof. Richard Greil MD

Head of the IIIrd Medical Department,
University Hospital Salzburg,
Paracelsus Medical University;
Salzburg Cancer Research Institute (SCRI);
Cancer Cluster Salzburg (CCS), Salzburg, Austria

Prof. Rebecca Dent MD FRCP (Canada)

Chair, Division of Medical Oncology & Senior Consultant,
National Cancer Center Singapore;
Professor, Duke-NUS Medical School, Singapore

Dr. Denise Wolf PhD

Senior Bioinformatics Scientist, Department of Laboratory
Medicine, University of California, San Francisco, CA, USA

Dr. Amrita Basu PhD

Assistant Professor, Department of Surgery,
University of California, San Francisco, CA, USA

Prof. Dr. Fritz Aberger

Molecular Cancer and Stem Cell Research, Lab Department
of Molecular Biology, University of Salzburg;
Cancer Cluster Salzburg (CCS), Salzburg, Austria

Assoc. Prof. Gabriel Rinnerthaler MD

IIIrd Medical Department, University Hospital Salzburg,
Paracelsus Medical University;
Salzburg Cancer, Research Institute (SCRI);
Cancer Cluster Salzburg (CCS), Salzburg, Austria

Luca Gianni MD

Chair, Breast Cancer Research Committee,
Michelangelo Foundation, Milan, Italy

Dr. Roberto Salgado

Department of Pathology,
GZA-ZNA Hospitals, Antwerp, Belgium;
Division of Research, Peter Mac Callum Cancer Center,
Melbourne, Australia

Prof. Pedro Romero MD

Deputy scientific managing director of the Lausanne Branch
of the Ludwig Institute for Cancer Research,
Department of Oncology, University of Lausanne,
Switzerland

Prof. Alexander Egle MD

IIIrd Medical Department, University Hospital Salzburg,
Paracelsus Medical University;
Salzburg Cancer, Research Institute (SCRI);
Cancer Cluster Salzburg (CCS), Salzburg, Austria

Dr. Iosifina Foskolou

Department of Haematopoiesis, Sanquin, Amsterdam, NL;
Department of Physiology, Development and Neuroscience,
Cambridge University, UK

Prof. Dr. Barbara Seliger

Director of the Institute for Medical Immunology,
Martin Luther University, Medical Faculty, Halle, Germany

Prof. Laurence Zitvogel MD PhD

Gustave Roussy Comprehensive Cancer Institute,
Villejuif, France;
Université Paris Saclay, Faculty of Medicine,
Le Kremlin-Bicêtre, France;
INSERM U1015, Villejuif, France

Berna C. Özdemir MD PhD

Department of Medical Oncology,
Bern University Hospital and University of Bern,
Switzerland

Prof. Giuseppe Curigliano MD PhD

Professor of Medical Oncology,
University of Milano;
Head of Division of New Drugs and Early Drug Development,
European Institute of Oncology IRCCS,
Milan, Italy

Priv.-Doz. Simon P. Gampenrieder MD

IIIrd Medical Department, University Hospital Salzburg,
Paracelsus Medical University;
Salzburg Cancer, Research Institute (SCRI);
Cancer Cluster Salzburg (CCS), Salzburg, Austria

Organization:

Richard Greil, Gabriel Rinnerthaler, Simon P. Gampenrieder

Salzburg Cancer Research Institute (SCRI) with

Laboratory of Immunological and Molecular Cancer Research (SCRI-LIMCR)

www.limcr.at and


Center for Clinical Cancer and Immunology Trials (SCRI-CCCIT)

www.cccit.at

in cooperation with the

Cancer Cluster Salzburg | www.cancercluster-salzburg.at and AGMT gemeinnützige GmbH | www.agmt.at

This event has been accredited with
11 DFP credits



Kindly supported by:

